biotech · Advanced Solid Tumors · Tumor, Solid · EIKN
Eikon Therapeutics
Eikon Therapeutics is a biotech organization headquartered in Millbrae, USA. It trades on NYSE under ticker EIKN. Primary therapeutic focus areas include Advanced Solid Tumors, Tumor, Solid, Advanced Melanoma, Advanced s
230 Harriet Tubman Way, Millbrae, CA 94030, US HQ
2019 Founded
404 Employees
Public company Type
EIKN · NYSE Ticker
Company details
- Status
- Public
- HQ
- 230 Harriet Tubman Way, Millbrae, CA 94030, US
- Founded
- 2019
- Employees
- 404
- Programs
- 15
- Drugs
- 13
- Patents
- 4
EIK1001-008
Phase 2 · small molecule · Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)
EIK1001-008 for Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC) is a Phase 2 program (small_molecule) at Eikon Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code EIK1001-008
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Eikon Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)
- Status
- active
- Trials
- 1